These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21360486)

  • 21. Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients.
    Goulielmos GN; Zervou MI; Myrthianou E; Burska A; Niewold TB; Ponchel F
    Gene; 2016 Jun; 583(2):90-101. PubMed ID: 26869316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor.
    Zamarrón C; Maceiras F; González J; Gómez-Reino JJ
    Respir Med; 2004 Feb; 98(2):123-5. PubMed ID: 14971874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.
    Bek S; Bojesen AB; Nielsen JV; Sode J; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2017 Oct; 17(5):403-411. PubMed ID: 28607508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis.
    Oliver J; Plant D; Webster AP; Barton A
    Biomark Med; 2015; 9(6):499-512. PubMed ID: 26079957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response to anti-TNF-alpha treatment: gene regulation at the bedside.
    de Vries N; Tak PP
    Rheumatology (Oxford); 2005 Jun; 44(6):705-7. PubMed ID: 15855186
    [No Abstract]   [Full Text] [Related]  

  • 26. Personalised treatment of arthritis in the next eRA.
    Tas SW
    Neth J Med; 2009 Dec; 67(11):362-3. PubMed ID: 20009111
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
    Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA.
    Pers YM; Cadart D; Rittore C; Ravel P; Daïen V; Fabre S; Jorgensen C; Touitou I
    Joint Bone Spine; 2014 Jul; 81(4):370-2. PubMed ID: 24462126
    [No Abstract]   [Full Text] [Related]  

  • 29. Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally".
    Lequerré T; Vittecoq O; Le Loët X
    Joint Bone Spine; 2005 Jul; 72(4):346-7; author reply 347-8. PubMed ID: 16038851
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomics of biological treatment in rheumatoid arthritis.
    Xie X; Zhang D; Chen JW; Tian J; Ling GH; Li F
    Expert Opin Biol Ther; 2014 Feb; 14(2):157-64. PubMed ID: 24295560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 32. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
    Robinson WH; Genovese MC; Moreland LW
    Arthritis Rheum; 2001 Sep; 44(9):1977-83. PubMed ID: 11592357
    [No Abstract]   [Full Text] [Related]  

  • 33. The new era in the treatment of rheumatoid arthritis.
    Putterman C
    Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):2-4. PubMed ID: 17694188
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A; Urano W; Tanaka E; Kamatani N
    Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic efficacy optimization--a step towards personalized medicine.
    Kiely PD
    Rheumatology (Oxford); 2016 May; 55(5):780-8. PubMed ID: 26424837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of biologic agents in rheumatoid arthritis: introduction.
    Silman AJ
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
    [No Abstract]   [Full Text] [Related]  

  • 37. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 38. Revolutionary change in rheumatoid arthritis management with biological therapy.
    Takeuchi T
    Keio J Med; 2011; 60(3):75-81. PubMed ID: 21979826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized medicine in rheumatoid arthritis: hopes and challenges.
    Bridges SL
    Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized therapies in pediatric inflammatory and autoimmune diseases.
    Stocco G; De Iudicibus S; Franca R; Addobbati R; Decorti G
    Curr Pharm Des; 2012; 18(35):5766-75. PubMed ID: 22726111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.